Despite the inconsistent results and the toxicity profile observed with anti-DLL3 treatment, DLL3 remains a promising target in SCLC, as it is homogeneously expressed on the surface of tumor cells in approximately 69% of SCLC cases and not in normal tissue [32,33]. The gene discussed is DLL3; the disease is neoplasm.